Skip to Content

Posts tagged with "Press Coverage"

  • Infectious Diseases

    And It Goes Like This

    It’s no wonder that there’s still so much argument over autism and vaccines. Paranoia is an endlessly renewable resource – big glowing hunks of it are always being dug out of the ground and put to use. For an unfortunately typical example, take a look at this piece from the New York Times. Some fifteen… Read More
  • Press Coverage

    A Day in the Life of Peter Rost

    I last wrote about Pfizer executive Peter Rost back in September, after he’d unburdened himself on the subject of Canadian drug reimportation. As readers will recall, his position on this issue is roughly that Canadian drug reimportation is a wonderful idea that needs to be implemented with all possible speed, which puts him rather at… Read More
  • Cancer

    Biotech At Last, Eh?

    There’s a recent piece in Business Week Online that says nice things about the biotech and pharma industries, and I should be happy about that. But there are so many misconceptions in it that I’m going to fisk the darn thing instead. After a lead-in which discusses a patient who responded to the Sugen/Pfizer kinase… Read More
  • Drug Prices

    Preach It, Brother

    Saturday’s New York Times had an astonishingly sensible article about the drug reimportation issue. (You can go ahead and insert the phrase “. . .especially for the New York Times“) Some highlights: “It may make political sense to point to Canada as a solution to high prescription drug prices in the United States. But many… Read More
  • Press Coverage

    Angell’s Book

    Update: (Much) more on this topic here. Readers are already asking me if I’ve read Marcia Angell’s new book, “The Truth About the Drug Companies.” I think that some of you are trying to do me in, hoping I’ll completely throw a piston rod or something. It’s a real possibility. Angell’s take on my industry… Read More
  • Drug Industry History

    The Old Days, Some Older Than Others

    Last Wednesday’s Wall Street Journal had a very interesting article on the front page: “In Two Generations, Drug Research Sees a Big Shift.” It profiles Leo Sternbach, discoverer of the diazepams (Valium being the most famous) and other drugs, and his son, Dan Sternbach of GlaxoSmithKline. The elder Sternbach has been at this stuf… Read More
  • Cardiovascular Disease

    Sic Transit Gloria Mundi

    So Entremed is finally giving up on its celebrated peptide drug candidates, angiostatin and endostatin. I’m sorry to see what the company, and its employees have been through, but I’m even sorrier when I think about what cancer patients have been through during this story. Especially those of them who read that (in)famous New York… Read More
  • Cancer

    Not Even Funny

    I’m late to this particular party – see Charles Murtaugh and Medpundit for the low-down on a particularly irritating LA Times column. (It requires registration to read, which is fairly irritating all by itself.) In a nutshell, the writer attempts to blame environmental factors for many cases of breast cancer, specifically chemicals prod… Read More
  • Cancer

    The Wall Street Journal versus the FDA

    Here we are again. Back in February (see the Feb. 27th post), the FDA asked for more data for Imclone’s cancer therapy, Erbitux, saying the existing studies were not sufficient to approve the drug. The Wall Street Journal’s editorial page threw a memorable fit about what they saw as the FDA’s intransigence (to which piece… Read More
  • Cancer

    Did He Say What They Thought He Said?

    I’ve received some mail pointing out that James Watson denied the “cure cancer in two years” quote which appeared in the 1998 Times article. I was aware of those denials, but (since you have to make a judgment call on these things,) I believe that he probably did say it. Why? First of all, because… Read More